Skip to search formSkip to main contentSkip to account menu

MK 8669

Known as: MK-8669, MK8669 
National Institutes of Health

Related topics

Related topics

2 relations
AP-23573

Broader (1)

ridaforolimus

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer.
2509 Background: The PI3K/AKT/mTOR signaling pathway is aberrantly activated in a variety of cancers. The combination of… 
2013
2013
A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
PurposeRidaforolimus (AP23573, MK-8669 or deforolimus) is an inhibitor of mammalian target of rapamycin (mTOR), an important… 
2012
2012
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial
PurposeAs part of a phase 1 dose-escalation trial, the pharmacodynamic activity of the mammalian target of rapamycin (mTOR… 
2011
2011
The effect of hepatic insufficiency on the pharmacokinetics of ridaforolimus.
e13001 Background: Ridaforolimus (RIDA) (AP23573; MK-8669), a unique rapamycin analog and a potent inhibitor of mTOR signaling… 
2010
2010
A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors.
9531 Background: The mTOR inhibitor ridaforolimus (R) has shown antitumor activity in adults with sarcomas and other malignancies… 
2010
2010
Abstract PR3: Preclinical and molecular profiling data suggest LumB breast cancer as a potential indication for co-targeting IGF1R and mTOR with MK-0646 and MK-8669
There has been increasing interest in developing cancer therapies targeting PI3K pathway nodes. However, inhibition of a single… 
Highly Cited
2008
Highly Cited
2008
Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669)
3509 Background: Deforolimus is a non-pro-drug rapamycin analog which specifically and potently inhibits mTOR. In Trial 202… 
2008
2008
Pharmacokinetics of oral deforolimus (AP23573, MK-8669)
14555 Background: Deforolimus is a non-pro drug rapamycin analog which specifically inhibits mTOR. Intravenous deforolimus has… 
2008
2008
324 POSTER Synergistic activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) and the anti-androgen bicalutamide in prostate cancer models
2008
2008
321 POSTER A phase I trial evaluating pharmacodynamics of deforolimus (AP23573, MK-8669) delivered orally on multiple dosing schedules
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)